NU1433-10 RAR-M Therapeutics Ltd The Provision of Business Consultancy to Assist Commercialisation of University Research.

Amyotrophic lateral sclerosis (ALS) - as with most other neurodegenerative diseases, including Alzheimer's and Parkinson's - is a major medical challenge and is having an ever-increasing impact upon the lives of patients, carers and indeed of society as a whole. Scientists at Durham (Chemistry Department) and Aberdeen Universities have recently designed, synthesised and identified a lead drug candidate with the potential for establishing a new treatment approach for ALS and with a longer-term potential of being effective for other neurodegenerative diseases.

The technology is now being patented and we are ready to develop a commercial vehicle to drive the drug development programme forwards and raise the necessary investment required for the next stages. The need for an experienced Business Executive/CEO, who has already delivered drugs to the market in the neurodegenerative area, is essential to support the Commercial Team and especially the CEO directly. Although two of the Team have commercial (spinout) experience (e.g. as CTO of LightOx who are successfully raising second phase major investment currently for LightOx), the successful launch of market leading drugs and the raising of the finance to make that happen is needed to successfully take the company forward.

In the longer term (such as Phase III raise of ca. £100+ million), such an executive might well be appointed as CEO, but in these early development stages, advise and business support is required